leadf
logo-loader
viewScancell Holdings PLC

Antibody collaboration deal for Scancell

Scancell Holdings (LON:SCLP) has signed its first deal with an unnamed antibody technology company to develop an early-stage technology created to kill tumour cells directly.

CEO Cliff Holloway tells Proactive London why this is significant and details how it complements Scancell's existing antibody technology.
News here too on what is unique about Scancell's antibody pipeline.

Quick facts: Scancell Holdings PLC

Price: 12.875 GBX

LSE:SCLP
Market: LSE
Market Cap: £81 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Scancell Holdings awarded funds from Innovate UK for COVID-19 vaccine

Scancell Holdings' (LON:SCLP) Dr Cliff Holloway talks to Proactive London's Katie Pilbeam after being awarded funds from Innovate UK to produce a COVID-19 vaccine. Holloway explains how the company is using their immunotherapies knowledge which is used in their cancer research projects to...

2 weeks, 6 days ago

2 min read